12 Health Care Stocks Moving In Friday's After-Market Session
Portfolio Pulse from Benzinga Insights
In Friday's after-market session, several healthcare stocks experienced significant movements. Aclarion (ACON) led the gainers with a 21.6% rise, while Atreca (BCEL) saw the largest decline among the losers, dropping 21.4%. Other notable movers included Outset Medical (OM), Absci (ABSI), and Cara Therapeutics (CARA) with positive gains, and Estrella Immunopharma (ESLA), Nektar Therapeutics (NKTR), and Revelation Biosciences (REVB) with declines.
January 12, 2024 | 9:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Absci's stock increased by 9.77% to $4.38, with a market value of $407.0 million.
Absci's notable after-market rise could be driven by investor confidence, potentially impacting the stock positively in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Aclarion's stock rose 21.6% to $3.82, with a market cap of $3.2 million.
A significant after-market rise often indicates positive investor sentiment which could lead to a short-term continuation of the upward trend.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Outset Medical's shares increased by 10.61% to $4.95, with a market value of $248.5 million.
The after-market gain for Outset Medical could suggest a positive short-term outlook, potentially due to investor optimism or reaction to company-specific news.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Atreca's stock decreased by 21.4% to $0.28, with a market value of $11.0 million.
A sharp decline in after-market trading typically indicates negative sentiment that could lead to further short-term losses.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Estrella Immunopharma shares declined by 10.57% to $1.1, with a market value of $38.7 million.
The after-market decline for Estrella Immunopharma may reflect investor concerns or negative reactions to news, suggesting a bearish short-term outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Nektar Therapeutics' stock fell by 6.41% to $0.5, with a market value of $95.3 million.
The decline in Nektar Therapeutics' stock price could signal short-term negative momentum, possibly due to market reactions or company-specific events.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
NEGATIVE IMPACT
Revelation Biosciences shares fell 5.03% to $0.45, with a market cap of $2.8 million.
A decrease in after-market trading for Revelation Biosciences could indicate a bearish sentiment among investors, potentially affecting the stock negatively in the short term.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100